Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

MyoSTAR Universal Satellite Cell-like Stem Cells for Muscle Regeneration: AI-powered Cell Engineering, Manufacturing and Precision Delivery

Coordinator
Myopax GmbH, Germany
Runs
1 September 2026 to 31 August 2031
Status
Running
EU funding
€9.7m
Total cost
€10.1m
Partners
8 organisations in 4 countries
Type
Research and Innovation Action
Grant agreement
101288213

What the project is doing

In the project's own words, from its summary on CORDIS.

MyoSTAR will develop the first scalable, allogeneic, off-the-shelf muscle stem cell therapy, placing Europe at the forefront of regenerative medicine. Muscle-wasting diseases and injuries affect over 20 million Europeans in emergency care, orthopedics, neurology, trauma, and iatrogenic settings, causing disability, loss of independence, premature death, and rising healthcare costs. Current treatments are mainly symptomatic and do not restore muscle function.

Skeletal muscle regenerates via satellite cells and autologous muscle stem cell therapies have shown promise, especially in pediatric and orphan diseases. Much of this innovation has been pioneered in Europe, with the consortium partner MyoPax among the leaders. Yet, broad use is limited by complex manufacturing, distribution limits, immune rejection, inconsistent quality and safety, and the lack of standardized delivery.

MyoSTAR will overcome these barriers by creating immune-cloaked, safety-equipped induced satellite cells (iSats) from hiPSCs - a universal, robust, readily available regenerative source. AI-powered quality control will ensure genomic integrity; closed-system GMP workflows will streamline manufacturing, and new potency assays will link in vitro function to in vivo regeneration. To ensure clinical adoption, a robotic injection system will deliver iSats with precision and consistency.

Seven leading partners from industry, biotech, and academia unite expertise to establish a fully preclinically validated, GMP- and regulator-ready iSat product, advancing to first-in-human trials in post-prostatectomy incontinence, a disabling condition with no regenerative option. Beyond this, the platform will expand to broader muscular diseases. By advancing stem cell engineering, AI-driven manufacturing, and precision delivery, MyoSTAR will create the first clinically ready, scalable platform for muscle regeneration offering realistic curative options and positioning Europe´s leadership in stem cell innovation.

Topics

Who is involved

OrganisationCityCountryRole
Myopax GmbHBerlinGermanyCoordinator
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Miltenyi Biotec BV & Co KgBergisch GladbachGermanyParticipant
TRI Thinking Research Instruments GmbHWedelGermanyParticipant
Aarhus UniversitetAarhus CDenmarkParticipant
MyoPax Denmark ApSCopenhagenDenmarkThird party
Fondazione Istituto Italiano Di TecnologiaGenovaItalyParticipant
Caeruleus Genomics LtdOxfordUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI